• United Therapeutics disclosed it will present new clinical data at the CHEST 2026 meeting in Phoenix on Oct. 18-21, 2026.
• An oral update will report how inhaled treprostinil performed in the TETON-IPF program in slowing disease worsening in idiopathic pulmonary fibrosis.
• Separate PHINDER analyses will be presented on mortality risk scoring in interstitial lung disease, supporting development of earlier screening approaches for PH-ILD.
• The FDA accepted an NDA for ralinepag in pulmonary arterial hypertension, keeping a potential new commercial product under review.
• The agency also accepted a supplemental NDA for nebulized treprostinil in idiopathic pulmonary fibrosis, positioning it as a second regulatory catalyst.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013239954) on October 13, 2026, and is solely responsible for the information contained therein.